Encouragingly, Ateeq et al. provided evidence supporting a rationale for targeting the SPINK1 in SPINK1+/ETS− PCas and demonstrated that combined monoclonal antibody treatment targeting both SPINK1 and epidermal growth factor receptor can cause more significant reduction in tumor formation than either monoclonal antibody alone, providing a strong evidence for targeted therapy for SPINK1+/ETS− PCas [37]. The gene discussed is SPINK1; the disease is neoplasm.